PMGC Holdings ELAB
NASDAQ ELAB
$6.66 +0.56 (+9.18%)
At close: Aug 21, 2026 · 4:00 PM EDT

PMGC Holdings (ELAB) Income towards Parent Company (2022 - 2026)

PMGC Holdings (ELAB) posted Income towards Parent Company of $19501.0 for Q1 2026, down 10.29% sequentially from $21738.0 in Q4 2025, and up 170.54% YoY from $7208.1 in Q1 2025.

PMGC Holdings (ELAB) Income towards Parent Company (2022 - 2026) Analysis & Trends

PMGC Holdings has reported Income towards Parent Company for 5 years, with the latest figure at $19501.0 in Q1 2026.

  • Quarterly Income towards Parent Company rose 170.54% year-over-year to $19501.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $80072.0 (up 105.71% YoY) and the FY2025 annual result came in at $32927.0, up 101.48% from the prior year.
  • Income towards Parent Company declined to $19501.0 in Q1 2026 per ELAB's latest filing, from $21738.0 in the prior quarter.
  • Over five years, Income towards Parent Company peaked at $1.1 billion in Q4 2022 and troughed at -$469.3 million in Q3 2022.
  • A 5-year average of $24.6 million and a median of -$299404.0 in 2024 frame the typical range for Income towards Parent Company.
  • The sharpest annual moves came in 2024 and 2026: Income towards Parent Company tumbled 121.83% in 2024, then soared 170.54% in 2026.
  • Over 5 years, Income towards Parent Company stood at $1.1 billion in 2022, then sank by 100.1% to -$1.1 million in 2023, then jumped by 79.96% to -$216910.0 in 2024, then soared by 110.02% to $21738.0 in 2025, then retreated by 10.29% to $19501.0 in 2026.
  • According to Business Quant data, Income towards Parent Company over the past three periods registered $19501.0, $21738.0, and $21698.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn -
10 PMGC Holdings 31.22 Mn 12.43 Mn 385,691.00

Historic Data

Download Data
DateValue
Mar 31, 2026 19,501.00
Dec 31, 2025 21,738.00
Sep 30, 2025 21,698.00
Jun 30, 2025 17,135.00
Mar 31, 2025 -27,644.00
Dec 31, 2024 -216,910.00
Sep 30, 2024 -299,404.00
Jun 30, 2024 -859,580.00
Mar 31, 2024 -1.87 Mn
Dec 31, 2023 -1.08 Mn
Sep 30, 2023 -270.32 Mn
Jun 30, 2023 -1.06 Mn
Mar 31, 2023 -843,918.00
Dec 31, 2022 1.11 Bn
Sep 30, 2022 -469.32 Mn